Circulation Research · 2020 · 111 citations · 37 references
Life SciencesCardiologyMolecular BiologyEpigeneticsGene ExpressionInflammationAtherosclerosis PharmacotherapyEndothelial ActivationEndothelial DysfunctionInflammatory SignalingAtherosclerosis Molecular MechanismsAtherosclerotic Endothelial ActivationAtherosclerotic Plaque CharacterizationAtherosclerotic Plaque RuptureEndothelial-leukocyte InteractionsMacrophage Inflammatory ResponsesPlaque StabilityPlaque Vulnerability
RATIONALE: Arterial inflammation manifested as atherosclerosis is the leading cause of mortality worldwide. Genome-wide association studies have identified a prominent role of HDAC (histone deacetylase)-9 in atherosclerosis and its clinical complications including stroke and myocardial infarction. OBJECTIVE: To determine the mechanisms linking HDAC9 to these vascular pathologies and explore its therapeutic potential for atheroprotection. METHODS AND RESULTS: deficiency reduces lesional macrophage content while increasing fibrous cap thickness thus conferring plaque stability. We demonstrate that HDAC9 binds to IKK (inhibitory kappa B kinase)-α and β, resulting in their deacetylation and subsequent activation, which drives inflammatory responses in both macrophages and endothelial cells. Pharmacological inhibition of HDAC9 with the class IIa HDAC inhibitor TMP195 attenuates lesion formation by reducing endothelial activation and leukocyte recruitment along with limiting proinflammatory responses in macrophages. Transcriptional profiling using RNA sequencing revealed that TMP195 downregulates key inflammatory pathways consistent with inhibitory effects on IKKβ. TMP195 mitigates the progression of established lesions and inhibits the infiltration of inflammatory cells. Moreover, TMP195 diminishes features of plaque vulnerability and thereby enhances plaque stability in advanced lesions. Ex vivo treatment of monocytes from patients with established atherosclerosis reduced the production of inflammatory cytokines including IL (interleukin)-1β and IL-6. CONCLUSIONS: Our findings identify HDAC9 as a regulator of atherosclerotic plaque stability and IKK activation thus providing a mechanistic explanation for the prominence of HDAC9 as a vascular risk locus in genome-wide association studies. Its therapeutic inhibition may provide a potent lever to alleviate vascular inflammation. Graphical Abstract: A graphical abstract is available for this article.
37
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Paul M. Ridker, Tom Thurén, Jean MacFadyen et al. · New England Journal of Medicine · 2017 · 9.1K citations · Full text
The support of human genetic evidence for approved drug indications
Matthew R. Nelson, Hannah Tipney, Jeffery L. Painter et al. · Nature Genetics · 2015 · 1.8K citations
Large-scale association analysis identifies new risk loci for coronary artery disease
Panos Deloukas, Stavroula Kanoni, Christina Willenborg et al. · Nature Genetics · 2012 · 1.7K citations · Full text
Medicine, Biostatistics, Cardiology +14
Duration of Nuclear NF-κB Action Regulated by Reversible Acetylation
Lin‐Feng Chen, Wolfgang Fischle, Eric Verdin et al. · Science · 2001 · 1.2K citations · Full text
Western Diet Triggers NLRP3-Dependent Innate Immune Reprogramming
Anette Christ, Patrick Günther, Mario Lauterbach et al. · Cell · 2018 · 1K citations · Full text